How does malignancy cause exudative pleural effusion?

What causes a malignant pleural effusion (MPE) to form? An MPE forms when cells from either a lung cancer or another type of cancer spread to the pleural space. These cancer cells increase the production of pleural fluid and cause decreased absorption of the fluid.

Table of Contents

Is malignant pleural effusion exudate or transudate?

MPE can be distinguished from many other clinical conditions by history and an exudative pleural fluid with cytology positive for malignancy. It is important to keep in mind that while MPE tend to be exudates, there is a small percentage (5-10%) that are transudative.

What causes pleural effusion exudative?

The most common causes of exudative effusions are pneumonia, cancer, pulmonary embolism, and tuberculosis. Evaluation requires imaging (usually chest x-ray) to confirm presence of fluid and pleural fluid analysis to help determine cause.

Does malignant pleural effusion mean lung cancer?

A pleural effusion can be serious and potentially life-threatening, but it is treatable. If cancer grows in the pleural space, it causes a “malignant pleural effusion.” This condition is a sign that the cancer has spread, or metastasized, to other areas of the body.

How serious is malignant pleural effusion?

Malignant pleural effusions (MPE) are a common terminal pathway for many cancers, with an estimated United States incidence of more than 150,000 cases per year. MPE is an aggressive disease with a uniformly fatal prognosis and a life expectancy of only 3 to 12 months.

Can a malignant pleural effusion be cured?

In most MPE patients, disease is not curable and the aim is palliative. The short-term aim is to relieve dyspnea. In the long term, the obliteration of pleural space to prevent the recollection of pleural fluid should be the main aim.

What is the life expectancy of malignant pleural effusion?

Malignant pleural effusion (MPE) is a common but serious condition that is related with poor quality of life, morbidity and mortality. Its incidence and associated healthcare costs are rising and its management remains palliative, with median survival ranging from 3 to 12 months.